DeepMed Research

University of Minnesota Masonic Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Phase 2

Recruiting

Conditions: Hematologic Malignancy
Minimal Residual Disease
PTPN11 Gene Mutation
Monosomy 7
Chromosome Abnormality
Acute Leukemia
Remission
TP53
Intrachromosomal Amplification of Chromosome 21
Myelodysplasia

Interventions: Drug: Fludarabine
Drug: Rituximab
Drug: Busulfan
Drug: Melphalan
Drug: Levetiracetam

First Posted Date: 2023-02-21

Last Posted Date: 2024-10-21

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 150

Registration Number: NCT05735717

Locations: 🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States

MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Phase 1

Terminated

Conditions: Peritoneal Cancer
Solid Tumor
Ovarian Cancer
Fallopian Tube Cancer
Cancer

Interventions: Drug: FT538
Biological: Enoblituzumab

First Posted Date: 2023-02-01

Last Posted Date: 2025-04-29

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 1

Registration Number: NCT05708924

Locations: 🇺🇸
Masonic Cancer Center - University of Minnesota, Minneapolis, Minnesota, United States

Assessing the Time Demands of Cancer

Active, not recruiting

Conditions: Metastatic Breast Cancer
Ovarian Cancer

First Posted Date: 2023-02-01

Last Posted Date: 2025-02-04

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 80

Registration Number: NCT05708703

Locations: 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸
Masonic Cancer Center - University of Minnesota, Minneapolis, Minnesota, United States

Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)

Phase 2

Withdrawn

Conditions: Prostate Cancer

Interventions: Drug: Abiraterone
Drug: Dutasteride

First Posted Date: 2023-01-31

Last Posted Date: 2023-02-27

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Registration Number: NCT05705700

Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia

Phase 1

Withdrawn

Conditions: HIV-1-infection
Lymphoid Tissue; Infection
Interleukin
ART
Cd4+ Lymphocyte Deficiency

Interventions: Biological: FT538
Drug: Vorinostat

First Posted Date: 2023-01-26

Last Posted Date: 2024-02-26

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Registration Number: NCT05700630

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Increasing HPV Vaccination in Pediatric, Adolescent, and Young Adult (PAYA) Cancer Survivors

Not Applicable

Recruiting

Conditions: HPV Associated Cancer
Cancer

Interventions: Behavioral: GLAm app

First Posted Date: 2022-12-27

Last Posted Date: 2024-12-06

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 490

Registration Number: NCT05665543

Locations: 🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States

Observational Study of Exposure to Environmental Toxicants Among Firefighters

Recruiting

Conditions: Healthy

Interventions: Other: Sample collection

First Posted Date: 2022-12-08

Last Posted Date: 2025-02-28

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 60

Registration Number: NCT05643014

Locations: 🇺🇸
Masonic Cancer Center, Minneapolis, Minnesota, United States

Evaluation of Intravenous Laronidase Pharmacokinetics Before and After Hematopoietic Cell Transplantation in Patients With Mucopolysaccharidosis Type IH.

Recruiting

Conditions: Hematopoietic Cell Transplantation
Mucopolysaccharidosis Type I

Interventions: Drug: Laronidase therapy and a stem cell transplant

First Posted Date: 2022-12-02

Last Posted Date: 2024-11-04

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 24

Registration Number: NCT05634512

Locations: 🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States

App-Assisted Day Reconstruction to Reduce Logistic Toxicity in Cancer

Completed

Conditions: Cancer

First Posted Date: 2022-08-16

Last Posted Date: 2024-07-03

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 23

Registration Number: NCT05502302

Locations: 🇺🇸
Masonic Cancer Center - University of Minnesota, Minneapolis, Minnesota, United States

QuitGuide for American Indians: Aims 2 & 3

Not Applicable

Completed

Conditions: Tobacco Use Disorder
Tobacco Use

Interventions: Behavioral: Standard QuitGuide app
Behavioral: Tailored QuitGuide app

First Posted Date: 2022-07-07

Last Posted Date: 2025-04-11

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 115

Registration Number: NCT05447156

Locations: 🇺🇸
Masonic Cancer Center - University of Minnesota, Minneapolis, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy